ERK2 inhibitor

DRUG CLASS:

ERK2 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

BRAF L597Q	Solid Tumor	BRAF L597Q	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
BRAF G469A	Solid Tumor	BRAF G469A	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
BRAF G469V	Solid Tumor	BRAF G469V	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
BRAF L485W	Solid Tumor	BRAF L485W	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
BRAF V600E	Melanoma	BRAF V600E	Melanoma	JSI-1187 Sensitive: C2 – Inclusion Criteria JSI-1187 Sensitive : C2	JSI-1187 Sensitive: C2 – Inclusion Criteria JSI-1187 Sensitive : C2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	LY3214996 Sensitive: C2 – Inclusion Criteria LY3214996 Sensitive : C2	LY3214996 Sensitive: C2 – Inclusion Criteria LY3214996 Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	ASN007 Sensitive: C2 – Inclusion Criteria ASN007 Sensitive : C2	ASN007 Sensitive: C2 – Inclusion Criteria ASN007 Sensitive : C2
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	ASN007 Sensitive: C2 – Inclusion Criteria ASN007 Sensitive : C2	ASN007 Sensitive: C2 – Inclusion Criteria ASN007 Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	ASN007 + ERAS-601 Sensitive: C2 – Inclusion Criteria ASN007 + ERAS-601 Sensitive : C2	ASN007 + ERAS-601 Sensitive: C2 – Inclusion Criteria ASN007 + ERAS-601 Sensitive : C2
BRAF V600E	Melanoma	BRAF V600E	Melanoma	LY3214996 Sensitive: C2 – Inclusion Criteria LY3214996 Sensitive : C2	LY3214996 Sensitive: C2 – Inclusion Criteria LY3214996 Sensitive : C2
BRAF L485W	Gallbladder Cancer	BRAF L485W	Gallbladder Cancer	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
BRAF G466A	Non Small Cell Lung Cancer	BRAF G466A	Non Small Cell Lung Cancer	ERAS-254 + LTT462 Sensitive: C3 – Early Trials ERAS-254 + LTT462 Sensitive : C3	ERAS-254 + LTT462 Sensitive: C3 – Early Trials ERAS-254 + LTT462 Sensitive : C3
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	ERAS-254 + LTT462 Sensitive: C3 – Early Trials ERAS-254 + LTT462 Sensitive : C3	ERAS-254 + LTT462 Sensitive: C3 – Early Trials ERAS-254 + LTT462 Sensitive : C3
KRAS G13D	Hepatocellular Cancer	KRAS G13D	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS Q61H	Hepatocellular Cancer	KRAS Q61H	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS A146T	Hepatocellular Cancer	KRAS A146T	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G12V	Hepatocellular Cancer	KRAS G12V	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G12S	Hepatocellular Cancer	KRAS G12S	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G12R	Hepatocellular Cancer	KRAS G12R	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G12D	Hepatocellular Cancer	KRAS G12D	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G12C	Hepatocellular Cancer	KRAS G12C	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G12A	Hepatocellular Cancer	KRAS G12A	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
NRAS Q61R	Hepatocellular Cancer	NRAS Q61R	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
NRAS Q61L	Hepatocellular Cancer	NRAS Q61L	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
NRAS Q61K	Hepatocellular Cancer	NRAS Q61K	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
NRAS Q61H	Hepatocellular Cancer	NRAS Q61H	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
KRAS G12D	Pancreatic Cancer	KRAS G12D	Pancreatic Cancer	ASTX029 Sensitive: C3 – Early Trials ASTX029 Sensitive : C3	ASTX029 Sensitive: C3 – Early Trials ASTX029 Sensitive : C3
KRAS G12A + BRAF D549N	Non Small Cell Lung Cancer	KRAS G12A + BRAF D549N	Non Small Cell Lung Cancer	ASTX029 Sensitive: C3 – Early Trials ASTX029 Sensitive : C3	ASTX029 Sensitive: C3 – Early Trials ASTX029 Sensitive : C3
BRAF D594G	Melanoma	BRAF D594G	Melanoma	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3

ERK2 inhibitor

ERK2 inhibitor

Associations(66)

Associations
(66)